This study presents the proportion of adults with intellectual disability using psychotropic medications including antipsychotics, antidepressants, anxiolytics, hypnotics and sedatives, and psychostimulants.
Methods:
A search was performed in PubMed, Embase, PsycINFO, Web of Science, and Scopus up to 31 December 2021. Articles were included if they reported the proportion of adults with intellectual disability using psychotropic medications. Frequency of use was estimated using a random effects meta-analysis. Meta-regression analysis was used to assess the association between study-level characteristics and variability in estimates, when heterogeneity was considerable.
Results:
Twenty-four articles were included in pooled analysis. The pooled prevalence of psychotropic medications was 41% (95% confidence interval: 35–46%). Pooled prevalences of subclasses were as follows: antipsychotics 31% (27–35%), antidepressants 14% (9–19%), anxiolytics 9% (4–15%), hypnotics/sedatives 5% (2–8%), and psychostimulants 1% (1–2%). Heterogeneity was considerable between studies, except for psychostimulants. There was no significant association between assessed characteristics and variability in prevalence estimates.
Conclusion:
Two-fifths of adults with intellectual disability were prescribed psychotropic medications. Antipsychotics and antidepressants were used by one-third and one-seventh of adults, respectively. There was considerable variability between studies, and further investigation is required to determine the source of variability. More studies are needed to better characterise prescribed psychotropic medications, including effectiveness and adverse effects, to ensure appropriate use of these drugs.
American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Washington, DC: American Psychiatric Association.
AxmonAEl MrayyanNEberhardJ, et al. (2019) Pharmacotherapy for mood and anxiety disorders in older people with intellectual disability in comparison with the general population. BioMed Central Psychiatry19: 238.
4.
BaileyN (2007) Prevalence of psychiatric disorders in adults with moderate to profound learning disabilities. Advances in Mental Health and Learning Disabilities1: 36–44.
5.
BeckCAWilliamsJVWangJL, et al. (2005) Psychotropic medication use in Canada. Canadian Journal of Psychiatry50: 605–613.
6.
BeltonAO’DwyerMPeklarJ, et al. (2018) Medication use and health screening in an ageing adult population with Down syndrome in Ireland: A descriptive study. Journal of Policy and Practice in Intellectual Disabilities15: 145–154.
7.
BensonTO’NeillSMurphyS, et al. (2015) Prevalence and predictors of psychotropic medication use: Results from the Northern Ireland Study of Health and Stress. Epidemiology and Psychiatric Sciences24: 542–552.
8.
BishopLMcLeanKJRubensteinE (2021) Epilepsy in adulthood: Prevalence, incidence, and associated antiepileptic drug use in autistic adults in a state Medicaid system. Autism25: 831–839.
9.
BowringDLTotsikaVHastingsRP, et al. (2017a). Challenging behaviours in adults with an intellectual disability: A total population study and exploration of risk indices. The British Journal of Clinical Psychology56: 16–32.
10.
BowringDLTotsikaVHastingsRP, et al. (2017b). Prevalence of psychotropic medication use and association with challenging behaviour in adults with an intellectual disability: A total population study. Journal of Intellectual Disability Research61: 604–617.
11.
BoyleAMelvilleCAMorrisonJ, et al. (2010) A cohort study of the prevalence of sleep problems in adults with intellectual disabilities. Journal of Sleep Research19: 42–53.
12.
BrettJKarangesEADanielsB, et al. (2017) Psychotropic medication use in Australia, 2007 to 2015: Changes in annual incidence, prevalence and treatment exposure. The Australian and New Zealand Journal of Psychiatry51: 990–999.
13.
BruinsmaEvan den HoofdakkerBJGroenmanAP, et al. (2020). Non-pharmacological interventions for challenging behaviours of adults with intellectual disabilities: A meta-analysis. Journal of Intellectual Disability Research64: 561–578.
14.
BucklesJLuckassonRKeefeE (2013) A systematic review of the prevalence of psychiatric disorders in adults with intellectual disability, 2003–2010. Journal of Mental Health Research in Intellectual Disabilities6: 181–207.
15.
CareyIMShahSMHoskingFJ, et al. (2016) Health characteristics and consultation patterns of people with intellectual disability: A cross-sectional database study in English general practice. The British Journal of General Practice66: e264–e270.
16.
CarfìARomanoAZaccariaG, et al. (2020). The burden of chronic disease, multimorbidity, and polypharmacy in adults with Down syndrome. American Journal of Medical Genetics. Part A182: 1735–1743.
17.
Carrasco-GarridoPHernández-BarreraVJiménez-TrujilloI, et al. (2016) Time trend in psychotropic medication use in Spain: A nationwide population-based study. International Journal of Environmental Research and Public Health13: 1177.
18.
ChokhawalaKStevensL (2020) Antipsychotic Medications. Treasure Island, FL: StatPearls Publishing.
19.
CooperS-ABaileyNM (2001) Psychiatric disorders amongst adults with learning disabilities-prevalence and relationship to ability level. Irish Journal of Psychological Medicine18: 45–53.
20.
CooperS-AHughes-McCormackLGreenlawN, et al. (2018) Management and prevalence of long-term conditions in primary health care for adults with intellectual disabilities compared with the general population: A population-based cohort study. Journal of Applied Research in Intellectual Disabilities31: 68–81.
21.
CooperS-AMcLeanGGuthrieB, et al. (2015) Multiple physical and mental health comorbidity in adults with intellectual disabilities: Population-based cross-sectional analysis. BioMed Central Family Practice16: 1–11.
22.
CooperS-ASmileyEJacksonA, et al. (2009). Adults with intellectual disabilities: Prevalence, incidence and remission of aggressive behaviour and related factors. Journal of Intellectual Disability Research53: 217–232.
23.
CooperS-ASmileyEMorrisonJ, et al. (2007a) Mental ill-health in adults with intellectual disabilities: Prevalence and associated factors. The British Journal of Psychiatry190: 27–35.
24.
CooperS-ASmileyEMorrisonJ, et al. (2007b) Psychosis and adults with intellectual disabilities. Social Psychiatry and Psychiatric Epidemiology42: 530–536.
25.
CrinoRSladeTAndrewsG (2005). The changing prevalence and severity of obsessive-compulsive disorder criteria from DSM-III to DSM-IV. The American Journal of Psychiatry162: 876–882.
26.
DebSThomasMBrightC (2001). Mental disorder in adults with intellectual disability. 1: Prevalence of functional psychiatric illness among a community-based population aged between 16 and 64 years. Journal of Intellectual Disability Research45: 495–505.
27.
DebSUnwinGDebT (2015). Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behavior. Journal of Intellectual Disability Research59: 11–25.
28.
DoanTNLennoxNGTaylor-GomezM, et al. (2013) Medication use among Australian adults with intellectual disability in primary healthcare settings: A cross-sectional study. Journal of Intellectual & Developmental Disability38: 177–181.
29.
DohertyAJAthertonHBolandP, et al. (2020) Barriers and facilitators to primary health care for people with intellectual disabilities and/or autism: An integrative review. British Journal of General Practice Open4: bjgpopen20X101030.
30.
DerSimonianRLairdN (1986) Meta-analysis in clinical trials. Controlled Clinical Trials7: 177–188.
31.
EggerMSmithGDSchneiderM, et al. (1997) Bias in meta-analysis detected by a simple, graphical test. British Medical Journal315: 629–634.
32.
EinfeldSLEllisLAEmersonE (2011). Comorbidity of intellectual disability and mental disorder in children and adolescents: A systematic review. Journal of Intellectual & Developmental Disability36: 137–143.
33.
EmersonEEinfeldSL (2011) Challenging Behaviour. Cambridge: Cambridge University Press.
34.
ESEMeD/MHEDEA Investigators, AlonsoJAngermeyerMC, et al. (2004). Prevalence of mental disorders in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatrica Scandinavica420: 21–27.
35.
FinlaysonJMorrisonJJacksonA, et al. (2010). Injuries, falls and accidents among adults with intellectual disabilities. Prospective cohort study. Journal of Intellectual Disability Research54: 966–980.
36.
FreemanMFTukeyJW (1950) Transformations related to the angular and the square root. The Annals of Mathematical Statistics21: 607–611.
37.
GoldneyRBainM (2006) Prevalence of psychotropic use in a South Australian population. Australasian Psychiatry14: 379–383.
38.
HálfdánarsonÓZoëgaHAagaardL, et al. (2017) International trends in antipsychotic use: A study in 16 countries, 2005–2014. European Neuropsychopharmacology27: 1064–1076.
39.
HarrisJC (2006) Intellectual Disability: Understanding Its Development, Causes, Classification, Evaluation, and Treatment. Oxford: Oxford University Press.
40.
HererGR (2012) Intellectual disabilities and hearing loss. Communication Disorders Quarterly33: 252–260.
41.
HawCKelbrickMStubbsJ (2012) A survey of antidepressant prescribing at a secure psychiatric hospital. Journal of Psychiatric Intensive Care8: 3–9.
42.
HigginsJPThompsonSGDeeksJJ, et al. (2003) Measuring inconsistency in meta-analyses. British Medical Journal327: 557–560.
HoveOHavikOE (2008) Mental disorders and problem behaviour in a community sample of adults with intellectual disability: Three-month prevalence and comorbidity. Journal of Mental Health Research in Intellectual Disabilities1: 223–237.
45.
HoyDBrooksPWoolfA, et al. (2012). Assessing risk of bias in prevalence studies: Modification of an existing tool and evidence of interrater agreement. Journal of Clinical Epidemiology65: 934–939.
46.
HuangYWangYWangH, et al. (2019) Prevalence of mental disorders in China: A cross-sectional epidemiological study. The Lancet Psychiatry6: 211–224.
47.
Hughes-McCormackLARydzewskaEHendersonA, et al. (2017) Prevalence of mental health conditions and relationship with general health in a whole-country population of people with intellectual disabilities compared with the general population. BJPsych Open3: 243–248.
48.
JanickiMPDaltonAJ (1998) Sensory impairments among older adults with intellectual disability. Journal of Intellectual and Developmental Disability23: 3–11.
49.
JanssenDGVermettenEEgbertsTC, et al. (2017) Prevalence of psychotropic medication use among Dutch Military personnel between 2003 and 2012 and its comparison to the Dutch general population. Military Medicine182: e1584–e1588.
50.
JobskiKHöferJHoffmannF, et al. (2017) Use of psychotropic drugs in patients with autism spectrum disorders: A systematic review. Acta Psychiatrica Scandinavica135: 8–28.
51.
JonesSCooperSASmileyE, et al. (2008) Prevalence of, and factors associated with, problem behaviors in adults with intellectual disabilities. The Journal of Nervous and Mental Disease196: 678–686.
52.
KarimEAlamMRahmanA, et al. (2006) Prevalence of mental illness in the community. TAJ: Journal of Teachers Association19: 18–23.
53.
KiernanCReevesDAlborzA (1995). The use of antipsychotic drugs with adults with learning disabilities and challenging behavior. Journal of Intellectual Disability Research39: 263–274.
54.
LangeSRehmJAnagnostouE, et al. (2018) Prevalence of externalizing disorders and Autism Spectrum Disorders among children with Fetal Alcohol Spectrum Disorder: Systematic review and meta-analysis. Biochemistry and Cell Biology96: 241–251.
LeunissenCLde la ParraNMTanIY, et al. (2011) Antiepileptic drugs with mood stabilizing properties and their relation with psychotropic drug use in institutionalized epilepsy patients with intellectual disability. Research in Developmental Disabilities32: 2660–2668.
57.
LiaoPVajdicCTrollorJ, et al. (2021) Prevalence and incidence of physical health conditions in people with intellectual disability: A systematic review. PLoS ONE16: e0256294.
58.
LiberatiAAltmanDGTetzlaffJ, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. Journal of Clinical Epidemiology62: e1–e34.
59.
LundqvistLO (2013). Prevalence and risk markers of behavior problems among adults with intellectual disabilities: A total population study in Örebro County, Sweden. Research in Developmental Disabilities34: 1346–1356.
60.
Maestre-MiquelCLópez-de-AndrésAJiZ, et al. (2021) Gender differences in the prevalence of mental health, psychological distress and psychotropic medication consumption in Spain: A nationwide population-based study. International Journal of Environmental Research and Public Health18: 6350.
61.
MaïanoCCoutuSTraceyD, et al. (2018) Prevalence of anxiety and depressive disorders among youth with intellectual disabilities: A systematic review and meta-analysis. Journal of Affective Disorders236: 230–242.
62.
MatsonJLMahanS (2010) Antipsychotic drug side effects for persons with intellectual disability. Research in Developmental Disabilities31: 1570–1576.
63.
MatthewsTWestonNBaxterH, et al. (2008). A general practice-based prevalence study of epilepsy among adults with intellectual disabilities and of its association with psychiatric disorder, behaviour disturbance and carer stress. Journal of Intellectual Disability Research52: 163–173.
64.
McClintockKHallSOliverC (2003). Risk markers associated with challenging behaviours in people with intellectual disabilities: A meta-analytic study. Journal of Intellectual Disability Research47: 405–416.
65.
McGillivrayJAMcCabeMP (2004) Pharmacological management of challenging behavior of individuals with intellectual disability. Research in Developmental Disabilities25: 523–537.
66.
McGrotherCWBhaumikSThorpCF, et al. (2006) Epilepsy in adults with intellectual disabilities: Prevalence, associations and service implications. Seizure15: 376–386.
67.
McMahonMHattonCBowringDL (2020) Polypharmacy and psychotropic polypharmacy in adults with intellectual disability: A cross-sectional total population study. Journal of Intellectual Disability Research64: 834–851.
68.
MelvilleCCooperSMorrisonJ, et al. (2008) The prevalence and determinants of obesity in adults with intellectual disabilities. Journal of Applied Research in Intellectual Disabilities21: 425–437.
69.
Meuwese-JongejeugdAVinkMVan ZantenB, et al. (2006) Prevalence of hearing loss in 1598 adults with an intellectual disability: Cross-sectional population based study. International Journal of Audiology45: 660–669.
70.
MoherDLiberatiATetzlaffJ, et al. (2010) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. International Journal of Surgery8: 336–341.
71.
MorganVALeonardHBourkeJ, et al. (2008) Intellectual disability co-occurring with schizophrenia and other psychiatric illness: Population-based study. The British Journal of Psychiatry193: 364–372.
72.
MunnZMoolaSRiitanoD, et al. (2014) The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. International Journal of Health Policy and Management3: 123.
73.
National Institute for Health and Care Excellence (2015) Challenging Behaviour and Learning Disabilities: Prevention and Interventions for People With Learning Disabilities Whose Behaviour Challenges [NG11]. National Health Services. Available at: https://www.nice.org.uk/guidance/ng11 (accessed 13 October 2022).
74.
O’DwyerMPeklarJMulryanN, et al. (2017) Prevalence, patterns and factors associated with psychotropic use in older adults with intellectual disabilities in Ireland. Journal of Intellectual Disability Research61: 969–983.
75.
OhayonMMCauletMPriestRG, et al. (1998) Psychotropic medication consumption patterns in the UK general population. Journal of Clinical Epidemiology51: 273–283.
76.
OlfsonMBlancoCLiuS-M, et al. (2012) National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Archives of General Psychiatry69: 1247–1256.
77.
PalayJTaillieuTLAfifiTO, et al. (2019). Prevalence of mental disorders and suicidality in Canadian provinces. Canadian Journal of Psychiatry64: 761–769.
78.
Paulose-RamRJonasBSOrwigD, et al. (2004) Prescription psychotropic medication use among the US adult population: Results from the third National Health and Nutrition Examination Survey, 1988–1994. Journal of Clinical Epidemiology57: 309–317.
79.
Paulose-RamRSafranMAJonasBS, et al. (2007) Trends in psychotropic medication use among US adults. Pharmacoepidemiology and Drug Safety16: 560–570.
80.
PereraBChenJKorbL, et al. (2021). Patterns of comorbidity and psychopharmacology in adults with intellectual disability and attention deficit hyperactivity disorder: An UK national cross-sectional audit. Expert Opinion on Pharmacotherapy22: 1071–1078.
81.
PerryBICooraySEMendisJ, et al. (2018). Problem behaviours and psychotropic medication use in intellectual disability: A multinational cross-sectional survey. Journal of Intellectual Disability Research62: 140–149.
RojasGFritschRGaeteJ, et al. (2005) Use of psychotropic medication in Santiago, Chile. Journal of Mental Health14: 407–414.
84.
RoomBTimmermansORoodbolP (2016). The prevalence and risk factors of the metabolic syndrome in inpatients with intellectual disability. Journal of Intellectual Disability Research60: 594–605.
85.
RuscioAMSteinDJChiuWT, et al. (2010). The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Molecular Psychiatry15: 53–63.
86.
ScheifesAWalravenSStolkerJJ, et al. (2016a). Adverse events and the relation with quality of life in adults with intellectual disability and challenging behaviour using psychotropic drugs. Research in Developmental Disabilities49–50: 13–21.
87.
ScheifesAWalravenSStolkerJJ, et al. (2016b) Movement disorders in adults with intellectual disability and behavioral problems associated with use of antipsychotics. Journal of Clinical Psychopharmacology36: 308–313.
88.
SharmaSKMudgalSKThakurK, et al. (2020) How to calculate sample size for observational and experimental nursing research studies?National Journal of Physiology, Pharmacy and Pharmacology10: 1–8.
89.
SheehanRHassiotisAWaltersK, et al. (2015) Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study. British Medical Journal351: h4326.
90.
SheehanRStrydomAMorantN, et al. (2017) Psychotropic prescribing in people with intellectual disability and challenging behaviour. British Medical Journal358: j3896.
91.
ShefflerZMAbdijadidS (2019) Antidepressants. Treasure Island, FL: StatPearls Publishing.
92.
SmileyE (2005) Epidemiology of mental health problems in adults with learning disability: An update. Advances in Psychiatric Treatment11: 214–222.
93.
SongMWareRSDoanTN, et al. (2020a) Appropriateness of psychotropic medication use in a cohort of adolescents with intellectual disability in Queensland, Australia. BJPsych Open6: e142.
94.
SongMWareRSDoanTN, et al. (2020b) Psychotropic medication use in adults with intellectual disability in Queensland, Australia, from 1999 to 2015: A cohort study. Journal of Intellectual Disability Research64: 45–56.
95.
SzökeABaudinGSabaG, et al. (2015) Prevalence of psychotic disorders in an urban area of France. BioMed Central Psychiatry15: 1–10.
TimehinCTimehinE (2004) Prevalence of hearing impairment in a community population of adults with learning disability: Access to audiology and impact on behaviour. British Journal of Learning Disabilities32: 128–132.
98.
TrollorJNSalomonCFranklinC (2016) Prescribing psychotropic drugs to adults with an intellectual disability. Australian Prescriber39: 126–130.
99.
TsiourisJAKimS-YBrownWT, et al. (2013) Prevalence of psychotropic drug use in adults with intellectual disability: Positive and negative findings from a large scale study. Journal of Autism and Developmental Disorders43: 719–731.
100.
TyrerPOliver-AfricanoPCAhmedZ, et al. (2008) Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: A randomised controlled trial. The Lancet371: 57–63.
101.
VoyerPCohenDLauzonS, et al. (2004) Factors associated with psychotropic drug use among community-dwelling older persons: A review of empirical studies. BioMed Central Nursing3: 1–13.
102.
WarburgM (2001) Visual impairment in adult people with intellectual disability: Literature review. Journal of Intellectual Disability Research45: 424–438.
103.
World Health Organization (2021) International statistical classification of diseases and related health problems (11th Rev. ed.). Available at: https://icd.who.int/browse11/l-m/en (accessed 13 October 2022).
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
